Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients at Baseline and CCRT Therapy
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
In this single armed, single-center, case-controlled study, the investigators will conduct a
prospective trial and integrate the most advanced imaging technology to medical practice,
attempting to solve the problem detected by radiomics approach. The investigators plan a
3-year project with non-randomized, single group assignment observational study design.
Thirty participants with diagnosed LACC that are to receive CCRT are to be recruited for this
prospective single institutional study from Chang Gung Memorial Hospital at Linkou (CGMH).
Standard-of-care MRI/CT that is required for staging will be the first line screening method.
A tumor biopsy and routine blood test will be obtained at the time of the initial clinic
visit. Participants eligible for this study will receive two investigative exams-MRF, CEST,
DNP-MRI MRI and Metabolomics, at baseline and the 2-week during CCRT.
The new imaging methods being tested are MRF and CEST without contrast enhancement, and
DNP-MRI which provides quantitative measurement of the metabolism occurring within cancer
cells. It also involves injection of a contrast agent-Hyperpolarized pyruvate (13C)
Injection. The participants will be injected with the study drug at a dose of 0.43 ml/kg and
then receive MRI scan.